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Abstract
Background: Paediatric rheumatology service in Sub-Sahara African is virtually not available as there is a shortage
of paediatric rheumatologists and other rheumatology health professionals. We aim to describe the clinical
spectrum and the frequencies of paediatric rheumatic diseases (PRDs) in Lagos State University Teaching Hospital
(LASUTH), Lagos, Nigeria.
Methods: This is a retrospective review of patients with PRDs seen over a five year period (March 2010 to February
2016) at the rheumatology clinic and children ward of LASUTH. We reviewed the folders of 57 patients from our
records. The demographics, baseline laboratory features, clinical diagnosis, treatment patterns and patient outcomes
were extracted and analyzed. Clinical and laboratory characteristics between patients with Juvenile idiopathic
arthritis (JIA) and patients with juvenile connective tissue diseases (JCTD) were compared using Fisher’s exact test.
Results: Fifty seven patients were studied with a female to male ratio of 3 to 1 (Female: 43; M: 14). The mean age at
presentation in years was 14 ± 4.4 years (range: 1.5–22 years). The mean duration of symptoms before diagnosis was
18.4 ± .9 months (range: 2–60 months). The diagnostic types of PRDs included 28(49.1%) cases of JIA. These were made
up of 14 cases of polyarticular JIA, nine cases of oligoarticular JIA and 5 cases of systemic onset JIA. Others were 18
(24.6%) cases of juvenile systemic lupus erythematosus (JSLE), 3 (5.3%) cases of joint hypermobility syndrome, 2 (3.5%)
cases of juvenile systemic sclerosis, 2 (3.5%) cases of fibromyalgia, 2 (3.5%) cases of plantar fasciitis, 1 (1.6%) case of
juvenile dermatomyositis (JDM), 1 (1.6%) case of juvenile polymyositis-systemic lupus erythematosus (PM-SLE) overlap,
1 (1.6%) case of secondary bilateral knee osteoarthritis from Blount disease, 1 (1.6%) case of secondary osteoporosis
from childhood leukemia and 1 (1.6%) case of Osgood-Schlatter’s disease. Constitutional symptoms and extra-articular
diseases were significantly more frequent among JCTD cases than among the JIA cases (Constitutional symptoms:
100% vs 83.3%, p = 0.003; extra-articular disease: 100% vs 10.7%, p = 0.001). The percentage mortality in this study was
10.5% while 20 (35.1%) of the patients were lost to clinic follow up.
Conclusion: The pattern of PRDs observed in this study is similar to that described in South African and North
American series but it differs from patterns reported in Asian series. Although hitherto largely unrecognized, PRDs may
constitute a substantial cause of morbidity and mortality in black Africans.
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Background
The burdens and impacts of malnutrition, poverty-related
and infectious diseases are well known in Sub-Sahara Africa.
There is however, little or no attention to non-communicable
diseases including paediatric rheumatic diseases (PRDs). The
shortage of paediatric rheumatologists and other rheumatol-
ogy health professionals as well as a general lack of awareness
of this subject often contribute to missing these diagnoses
and a consequent perception of rarity of PRDs in Africa [1].
In developing countries, prevalence estimates of PRDs are
usually difficult to determine. This is especially so in Africa
where access to pediatric rheumatology service is rare [2]. In
Singapore, the prevalence of true PRDs among all cases re-
ferred to childhood rheumatology clinic is 57.8%, while in
four Canada provinces, the prevalence estimates over 9 to
14 year period for systemic autoimmune rheumatic diseases
(SARD) is 2 SARD cases per 10,000 residents aged 18 or less
[3, 4]. However, this estimate did not include frequency of in-
dividual SARD. The frequencies and spectrums of PRDs vary
in different studies from the western hemisphere and Asia.
Whilst some studies from North America and Europe have
reported JIA as the most frequent PRD, a study from Asia
found systemic vasculitis as the most common [3, 5–8]. In
Africa, there are few reports on PRD conditions such as JIA,
juvenile systemic lupus erythematosus (JSLE), and juvenile
dermatomyositis (JDM) [9–11]. However, there is a dearth of
reports on the frequencies and spectrums of PRDs in various
Sub-Saharan African settings [1]. A hospital-based report of
the spectrum of PRDs in two tertiary institutions in South
Africa has documented a relative frequency of 33.3% for JIA
and 10.2% for juvenile connective tissue diseases (JCTD)
[12]. Also, inflammatory arthritides were the most frequent
musculoskeletal conditions among Kenyan children in out-
patient clinics and wards [13, 14]. Patients with JCTD were,
however, not included in the Kenyan studies. In a new
rheumatology clinic in Zambia, Chipeta et al. registered 230
pediatric rheumatic cases over 2 years but the pattern of the
PRDs was not stated in their report [15].
Epidemiological reports of PRDs in Africa are hampered
by the lack of trained professionals in the field of rheuma-
tology. Therefore, the burden of these diseases is un-
known. Moreover, cases are often misdiagnosed or under-
diagnosed and this is helped by a number of factors. One
is the widespread belief that arthritis does not occur in
children. Also, the much higher rate of infectious condi-
tions often poses a lot of confusion and tends to lead to a
delay in definitive diagnosis. Clinicians might believe they
are dealing with an occult infection over a sustained
period in a true case of rheumatic disease.
To the best of our knowledge, there have been no pub-
lished reports of the spectrums of PRDs among West
Africans. This is a retrospective study of the types and
frequencies of PRDs in Nigerians attending a tertiary teach-
ing hospital.
Methods
This is a retrospective review of PRD cases managed be-
tween the first week of March 2010 and the last week of
February 2016 at the adult rheumatology unit of LASUTH.
LASUTH is a tertiary teaching hospital in the cosmopolitan
city of Lagos. The hospital has one of the two adult
rheumatology clinics in the city. There is no paediatric
rheumatology clinic in Nigeria and as such pediatric
rheumatic patients are managed by adult rheumatologists
in conjunction with paediatricians. The paediatric patients
with either musculoskeletal complaints or systemic symp-
toms suspicious of a rheumatic disease were referred for
rheumatology review from the paediatric clinic, peripheral
hospitals or paediatric wards. The diagnosis of PRDs was
based on validated criteria such as the American College of
Rheumatology (ACR) classification criteria, International
League of Association of Rheumatology criteria, and other
validated criteria for rheumatic diseases. The entry criterion
for case selection was the diagnosis of a PRD in the pa-
tient’s record either as paediatric-onset disease in adult or a
paediatric-age patient. Paediatric was defined as disease on-
set before the 16th birthday in all cases except JSLE where
disease onset before the 18th birthday was adopted. The
hospital records were retrieved for each patient and details
of biodata, baseline clinical parameters, baseline laboratory
indices, clinical diagnoses, drug treatments and patient out-
comes were extracted. The duration of symptoms was
taken as the onset from the first symptoms to clinical diag-
nosis at our facility. The full blood count, haematocrit, and
erythrocyte sedimentation rate were documented in 50
cases (87.7%). Furthermore, C-reactive protein and serum
ferritin were recorded for 37 cases (64.9%). Antinuclear
antibody (ANA) was recorded in 48 cases(84.2%) while
anti-extractable nuclear antigen (ENA) was documented in
16 patients(28.1%). Rheumatoid factor (RF) was recorded in
seven patients (12.3%). ANA and ENA were analyzed by
Enzyme-linked immunosorbent assay (ELISA) methods
and RF was assayed by nephelometry.
Statistical methods
Fisher’s exact test was applied to compare the clinical and
laboratory characteristics between patients with JIA and
patients with JCTD. All statistical analyses were done
using the SPSS version 21(IBM USA, Armonk, NY
10504). A p value <0.05 was considered to be significant.
Ethical approval was granted by the research and ethics
committee of Lagos State University Teaching Hospital
(LASUTH)
Results
A total of 57 patients with PRDs, which included 11 cases
diagnosed in pediatric ward, 30 referred cases from gen-
eral paediatric clinic, and 16 patients referred from per-
ipheral hospitals were managed at the adult rheumatology
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unit. These accounted for 2.4% of the 2330 rheumatic
cases diagnosed and managed in our institution over the
study period. As shown in Table 1, three quarters of our
PRD cases were female and the mean age at presentation
was 14 years. The mean duration of symptoms before the
diagnosis was made was 18 months and musculoskeletal
pain was documented in 52 (92%) PRD cases.
PRDs in 57 Nigerian children
As shown in Table 2, JIA was the most frequent PRD
seen in 28 (49%) of all cases. Polyarticular JIA(50%) was
the most frequent of the three types of JIA observed. A
total of 18 JCTD cases were seen. These accounted for
31.6% of all PRDs. They include 14 cases of JSLE, two
cases of juvenile systemic sclerosis, and a case each of
juvenile dermatomyositis and PM-SLE overlap.
Laboratory features
As shown in Table 3, 23 patients had positive ANA
while 13 patients had positive ENA antibody. Anaemia
was recorded in 37 PRD patients (74%) while rheuma-
toid factor was positive in two patients with polyarticular
JIA. The mean haematocrit was 27.7% while the mean
ESR was 72.9 mm/h.
The JCTD cases seen include JSLE, juvenile systemic
sclerosis, juvenile dermatomyositis, and PM-SLE overlap.
In addition to JIA, these five diagnoses constituted the
chronic inflammatory rheumatic disorders managed. Con-
stitutional symptoms such as progressive weight loss, re-
current fever and fatigue were present in all patients with
JCTD while constitutional symptoms were found in 15
(53.6%) patients with JIA (p < 0.001). Elevated ESR was
found in 15 (83.3%) of JCTD patients and 25 (89.3%) of
JIA patients. However, the difference in these proportions
was not statistically significant (p = 0.666). Extra-articular
manifestations included organ based features such as
nephritis, pneumonitis and uveitis which excluded the
musculoskeletal and constitutional symptoms; and they
were found in all 18 (100%) patients with JCTD and 3
(10.7%) patients with JIA (p < 0.001).
Table 1 Baseline demographic and clinical characteristics of 57
Nigerian children with PRDs
n (%) Range Mean(±SD)
Female 43(75.4)
Male 14(24.6)
Age at presentation (years) 1.5–22 14(±4.4)





Table 2 Spectrum of PRDs in 57 Nigerian children
Pediatric rheumatic diseases Frequency (%)
Chronic inflammatory rheumatic diseases
Juvenile idiopathic arthritis 28(49.1)
Systemic onset JIA 5(17.8)
Polyarticular JIA 14(50)
Oligoarticular JIA 9(31.2)
Juvenile connective tissue diseases (JCTD)
JSLE 14(24.6)




Joint hypermobility syndrome 3(5.3)
Isolated plantar fasciitis 2(3.5)
Fibromyalgia 2(3.5)




JSLE juvenile systemic lupus erythematosus, PM-SLE overlap
polymyositis-systemic lupus erythematosus overlap
Table 3 Laboratory characteristics of Nigerian children with PRDs
Laboratory abnormalities Total number
of PRD cases tested
n (%)
Anaemia(haematocrit < 33%) 50 37(74)
Elevated ESR(ESR > 20 mm/h) 50 42(84)
Elevated CRP(CRP > 8 mg/l) 37 32(86.4)
Elevatedferritin
(Ferritin > 150 μg/l)
37 27(72.9)
Elevated RF(Rh-factor > 30iu/ml) 7 2(28.6)
Positive Anti-nuclear antibody 48 23(47.9)
Positive Anti-ENA antibody 16 13(81.2)
Laboratory parameters in SARDs Mean(±SD) Range
Haematocrit (%) 27.7(±7.5) 14–42
ESR (mm/h) 72.9(±37.4) 4–142
WBC (/μL) 11,081(±8,742) 1,350–45,600
Platelet count (/μL) 336,166(±191,938) 81,200–820,000
CRP (mg/L) 8.1(±4.9) 3–21
Ferritin(mg/dl) 548.5(±273.4) 62–2,140
PRD paediatric rheumatic disease, ESR erythrocyte sedimentation rate, CRP C -
reactive protein, ENA Extractable nuclear antigen, WBCwhite blood cell.
Normal reference range from our laboratory: Haematocrit-33-45%, ESR-0-
20 mm/h, WBC-4500-13500/μL, Platelet count-
150,000-450,000/μL,CRP-0-8 mg/l, ferritin-10-150 μg/l
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Treatment and outcome patterns in Nigerians with PRDs
Non-steroidal anti-inflammatory drugs (NSAIDs) were
used for treatment in 40 (70.1%) cases while oral prednis-
olone was used in 32 (56.1%) cases. Twenty-five (43.8%)
patients with JIA had methotrexate while all cases with
JSLE had hydroxychloroquine. Five patients had biologic
agents (rituximab in four and etanercept in one) out of 18
biologic-eligible patients. Rituximab was used in four JSLE
patients with refractory lupus nephritis unresponsive to
prednisolone, hydroxychloroquine, and azathioprine or
mycophenolate mofetil while etanercept was administered
in one refractory rheumatoid factor-positive polyarticular
JIA patient. This latter patient happened to be the only
survivor among all patients that had biologics. There were
six mortalities accounting for 10.5% of the PRD cases
while 20 (35.1%) patients were lost to follow up. Four
mortalities were in patients with JSLE while two were in
patients with systemic onset JIA. Progressive renal failure
from lupus nephritis was the cause of mortality in the de-
ceased JSLE patients. While one patient with systemic on-
set JIA died from overwhelming sepsis, the other died
from suspected macrophage activating syndrome.
Discussion
This is a report of patients with PRDs seen over a 5-year
period by an adult rheumatology team. PRDs accounted for
2.8% of all inpatient and outpatient rheumatic cases managed
over the period. This contrasts with the prevalence of 57.8%
documented in childhood rheumatic clinic in Singapore [3].
This difference may be attributed to the primary adult focus
of our unit. We noted that the mean age of presentation in
our series is higher than the mean age reported among US
patients with PRD (14 ± 4.4 years vs 7 ± 5.76 years) [16].
Besides, Nigerian patients with PRDs have high mean dur-
ation of symptoms before diagnosis (18.2 months). Late pres-
entation and delayed diagnosis may be due to poverty,
ignorance, and inadequate healthcare infrastructures and
personnel. The inclusion of patients older than 18 years with
retrospective diagnoses of childhood-onset diseases may also
explain the high mean age of presentation observed in this
series. There are no paediatric rheumatology clinics or paedi-
atric rheumatologists in Nigeria. However, delay in diagnosis
was also documented in the USA, a country with about 300
certified pediatric rheumatologists [17]. The report stated that
60% of children referred for suspected rheumatic conditions
did not have confirmed rheumatic diagnosis and further
rheumatologic follow up was requested in 40% of cases. The
complex tendencies of many JCTD may inherently present
diagnostic difficulties and sometimes prolong the period of
evaluation before a diagnosis is made. Moreover, the near
similar manifestations of JCTD with common childhood in-
fections and malignancies may lead to initial diagnostic con-
fusions in lower hospitals contributing to the delay in
presenting for rheumatologist care.
We observed that PRDs are more frequent among fe-
male patients than in the male patients. This observation
may be due to the substantial proportion of JCTD and JIA
cases in our study as these conditions are generally more
common in the female than in the male [4]. The most fre-
quent clinical feature among our patients was musculo-
skeletal pain occurring in 91.2% while constitutional
symptoms were recorded in 57.9% of PRD cases. Similarly,
it was observed in Canada that musculoskeletal pain was
the most common presenting complaint in a children
rheumatology clinic [17]. In addition, they found that joint
swelling and fever were most predictive of the need for
further rheumatology follow up in their clinic.
JIA is the most frequent PRD condition identified in this
study accounting for 49.1% of PRD cases. This is followed
by JSLE in 24.6% of the study subjects and JCTD, on the
whole, constituted 36.1% of PRD subjects. This result is in
consonance with various studies from Europe, South Africa
and USA that documented JIA as the most frequent PRD
while either juvenile lupus or all CTDs was the next in their
reports [12, 16, 18]. Previous reports from Africa suggest
that JIA, JSLE, and JDM may not be uncommon in Sub-
Saharan Africa [9, 10, 19]. Systemic vasculitis was the com-
monest PRD observed in Singapore by Tan et al. and it was
found in a low proportion (4.3%) in a South African series
but we did not document any systemic vasculitis in our
series [3, 12]. Geographical variations in the frequencies of
vasculitides are likely to be the reason for this finding. We
found a low proportion of non-inflammatory rheumatic
conditions such as joint hypermobility syndrome, isolated
plantar fasciitis, fibromyalgia, and secondary osteoarthritis
in our series. Orthopedic surgeons in our hospital often
manage children with mechanical and non-inflammatory
PRDs. This may explain the low frequency of this category
of cases in this study.
Patients with a high clinical likelihood of a particular PRD
had laboratory investigations tailored to that condition. This
policy was adopted in our center to reduce the cost and
burden of investigations on our patients as most of these
patients pay directly for their laboratory investigations. The
proportion of PRD cases with anaemia and elevated ESR in
this study is high. This is due to a high proportion of sub-
jects with SARDs in this study. Although, the proportions of
nutritional anaemia and occult parasitaemia were not
estimated in our patients, they may contribute to the high
percentage of subjects with anaemia in our study.
We face enormous challenges in Africa with regards to
anti-rheumatic medications. In Nigeria, numerous NSAIDs
and oral prednisolone are readily available over the counter
and patients often self-medicate with them before seeking a
physician’s review. Moreover, some synthetic disease-
modifying anti-rheumatic drugs (DMARDs) are not readily
available and when they are available, they may be unafford-
able for many patients. Doctors and patients sometimes
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source for DMARDs from other countries often at prohibi-
tive costs. Standard therapy with NSAIDs, DMARDs and
glucocorticoids were administered to the majority of our pa-
tients with chronic inflammatory rheumatic diseases. Access
to biologic DMARDs is limited in most African countries
and this often limits the quality of specialist care a patient
could get [20]. The highly limited access to biologics is a
problem in the developing world where patients often fail to
get access to specialist care until late in their disease. Rituxi-
mab and Etanercept, the only biologic DMARDs available in
Nigeria, are largely unaffordable for our patients who have
to pay for their treatment.
JSLE contributed four out of the six deaths and all these
four patients had lupus nephritis unresponsive to standard
therapy. Also, they had rituximab infusions in addition to
other supportive care. However; they died from progres-
sive renal failure after haemodialysis was instituted. The
other two patients had systemic JIA and the causes of
death in them were overwhelming sepsis and suspected
macrophage activating syndrome. Systemic lupus erythe-
matosus has been shown to run a more severe and more
aggressive course in blacks and, even worse, in children
[21]. Long delays before the diagnoses were made and in-
adequate treatments due to financial difficulties may have
contributed to the high short-term mortality. In addition,
some studies have suggested that socio-demographic dis-
parities may influence the outcomes of these younger sub-
jects [21, 22]. The proportion of PRD cases lost to follow
up in this study was 35.1%. This high rate of discontinu-
ation of care plan reflects the common pattern of unsus-
tained treatment adherence among our patients. Poverty,
illiteracy and various health related cultural beliefs may
contribute to this phenomenon. Our study is also limited
by a small sample size and the retrospective nature of the
design. The burden of PRDs may have been under-
appreciated due to the adult focus of our practice as there
is no paediatric rheumatologist in our country. Further-
more, high default rate among our patients makes the ac-
tual treatment outcome difficult to determine. Prospective
cohort studies on this subject will help to determine the
course of PRDs and their outcomes among Nigerians.
Conclusions
The spectrum of PRDs observed in this Nigerian series
shares some similarities with patterns described in earlier
studies from South Africa, North America and Europe. In all
of these studies JIA accounts for the largest number of PRDs.
Our patients with JIA tend to be younger than the patients
presenting with JCTDs. However, systemic vasculitides, the
most frequent PRDs in Singapore, were not observed in our
series. The Nigerian patients with PRDs are more likely to be
female, are more likely to present to the hospital later than
children from the West and are more likely to present with
musculoskeletal complaints than other symptoms.
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